Gsa Capital Partners LLP Agios Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$21.32 - $34.81 $1.56 Million - $2.55 Million	-73,262 Reduced 70.37%	30,853 $902,000
Q4 2023 Feb 16, 2024	BUY	$19.97 - $24.53 $2.08 Million - $2.55 Million	104,115 New	104,115 $2.32 Million
Q3 2022 Nov 14, 2022	BUY	$19.51 - $34.14 $175,316 - $306,782	8,986 New	8,986 $254,000
Q1 2022 May 11, 2022	SELL	$26.68 - $34.81 $1.55 Million - $2.02 Million	-58,059 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$29.58 - $49.78 $1.72 Million - $2.89 Million	58,059 New	58,059 $1.91 Million
Q4 2020 Feb 03, 2021	SELL	$33.21 - $46.54 $582,901 - $816,870	-17,552 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$33.87 - $55.93 $594,486 - $981,683	17,552 New	17,552 $614,000
Q4 2019 Feb 12, 2020	SELL	$30.08 - $50.59 $353,861 - $595,140	-11,764 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$32.4 - $49.58 $137,246 - $210,020	4,236 Added 56.27%	11,764 $381,000
Q2 2019 Aug 06, 2019	BUY	$46.17 - $68.1 $347,567 - $512,656	7,528 New	7,528 $375,000
Q4 2018 Feb 12, 2019	SELL	$42.73 - $76.53 $145,282 - $260,202	-3,400 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$71.67 - $91.95 $243,678 - $312,630	3,400 New	3,400 $262,000

232

58.1M

403K

469K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $3.24B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.